# Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

> **NCT02421679** · PHASE2 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 159 (actual)

## Conditions studied

- PTSD

## Interventions

- **DRUG:** TNX-102 SL

## Key facts

- **NCT ID:** NCT02421679
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-14
- **Primary completion:** 2016-05-26
- **Final completion:** 2016-05-26
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02421679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02421679, "Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02421679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*